What Is the Cost-Effectiveness of Pola-R-CHP in DLBCL?

By Chadi Nabhan, MD, MBA, FACP - Last Updated: March 23, 2023

Swetha Kambhampati, MD, and Nikhil Thiruvengadam, MD, discuss the implications of their study investigating the cost effectiveness of pola-R-CHP in previously untreated DLBCL with host Chadi Nabhan, MD, MBA, FACP, in this episode of The HemOnc Pulse.

Catch up on earlier episodes of The HemOnc Pulse here.

Dr. Osman on Identifying and Treating High-Risk MDS

Dr. Rami Komrokji on Trends in Real-World MDS Care

Discussing the Role of MRD in CLL With Talal Hilal, MD

What are the Controversies Surrounding MRD in Blood Cancers?

HMAs Are ‘Cornerstone’ in High-Risk MDS Treatment, Says Jamile Shammo, MD

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

What Is the Cost-Effectiveness of Pola-R-CHP in DLBCL?

Related